NON-SMALL CELL LUNG CANCER (NSCLC)

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy (cemiplimab) can help shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 60 participants will receive the combinati…

This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not h…

This study tested whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 1,186 adults with metastatic NSCLC who had not re…

This early-stage study tests a new drug called furmonertinib in about 160 people with advanced or spreading non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to see if the drug is safe and can shrink tumors. Participants must have alre…

This study tests an experimental oral drug, IMM-1-104, in people with advanced solid tumors that have RAS mutations. The goal is to find a safe dose and see if it can shrink tumors, either alone or with other approved drugs. About 209 adults with pancreatic cancer, melanoma, or l…

This early-stage study tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS mutation. The treatment uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to ch…

This early-stage study tested a new drug called HER3-DXd in 312 people with advanced non-small cell lung cancer (NSCLC) that had spread or couldn't be removed. The goal was to check safety and see if the drug could shrink tumors. Participants had specific genetic changes (EGFR or…

This study tests whether adding a precise type of radiation (SABR) to the targeted drug osimertinib can help people with advanced EGFR-mutant lung cancer live longer without their disease getting worse. About 41 adults with this specific genetic type of lung cancer will receive b…

This early-phase trial tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in adults with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check safe…

This study tests three new drug combinations (adding S095018, S095024, or S095029 to cemiplimab) in 102 adults with advanced non-small cell lung cancer that has high PD-L1 and hasn't been treated before. The goal is to see if these combos are safe and can shrink tumors. This is n…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This program provides early access to telisotuzumab vedotin, an investigational drug for non-small cell lung cancer (NSCLC), before it is officially approved. It is for patients who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must de…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside thei…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 people with advanced or metastatic non-small cell lung cancer that has specific genetic changes (EGFR mutations or others) and has already been treated. The goal is to see if MK-287…

This study tests an experimental drug called RP1, a virus that attacks cancer cells, given alone or with the immunotherapy nivolumab. About 340 adults with advanced lung cancer, skin cancer, or certain other solid tumors will receive the treatment. The goal is to see if the combi…

This program provides access to the drug ceritinib (LDK378) for patients with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options and cannot join a clinical trial. It is designed for individual patients whose doctors request the …

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a powerful chemotherapy directly to cancer cells, aiming to shrink tumors whi…

This study tests whether adding olaparib to durvalumab can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy and durvalumab will receive either the combination or a place…

This study tests a new drug, MK-2870, against standard chemotherapy in 520 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has worsened after targeted therapy. The main goal is to see if MK-2870 helps people live longer. Participants are…

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors (like lung, bladder, or breast cancer). The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be…

This study looks at how well brigatinib works as the first treatment for adults with a specific type of lung cancer called ALK-positive non-small cell lung cancer. The main goal is to see how long the cancer stays under control without getting worse. Researchers will also measure…

This study compares two ways of taking tissue samples from lung cancer patients to see if having a specialist check the sample right away helps get enough tissue for genetic testing. About 349 adults with known or suspected non-small cell lung cancer will take part. The goal is t…

This early-phase study uses special PET scans to see where two experimental drugs (BI 765063 and BI 770371) go in the body and how much they reach tumors. About 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments will receive one…

This study looks at whether a personalized blood test can detect the return of early-stage non-small cell lung cancer before standard imaging like CT scans. Researchers will follow 450 patients after surgery, using a custom test based on each person's tumor DNA. The goal is to se…

This study observes 404 adults in Italy with advanced non-small cell lung cancer who are starting treatment with the immunotherapy drugs nivolumab and ipilimumab. Researchers will collect real-world data on how well the treatment works, side effects, and patient characteristics. …

This study follows 160 people with lung cancer to see how their muscle mass, strength, and function relate to how well they tolerate treatment, their quality of life, and survival. Researchers want to understand why some patients struggle to complete their cancer therapy. The goa…

This study looks at how long Chinese patients with advanced ALK-positive non-small cell lung cancer stay on the drug brigatinib when it's used as their first treatment. Researchers will also track how long the cancer stays under control and how patients respond. About 154 partici…

This study observes 300 adults with advanced non-small cell lung cancer whose tumors have very low PD-L1 levels (below 1%). Researchers are tracking side effects and healthcare use from first-line treatments like nivolumab plus ipilimumab, with or without chemotherapy. The goal i…